Have a personal or library account? Click to login
Correction factor between two calcitonin assays: DiaSorin LiaisonXL and Cobas E601 Cover

Correction factor between two calcitonin assays: DiaSorin LiaisonXL and Cobas E601

Open Access
|Jul 2021

References

  1. 1. Gardner DG, Shoback MD. Metabolic bone disease. In: Greenspan’s Basic & Clinical Endocrinology, Tenth Edition. Ohio: McGraw-Hill; 2018. p. 239-297.
  2. 2. Castagna MG, Fugazzola L, Maino F, Covelli D, Memmo S, Sestini F, et al. Reference range of serum calcitonin in pediatric population. J Clin Endocrinol Metab. 2015 May;100(5):1780-4. DOI: 10.1210/jc.2014-450810.1210/jc.2014-450825955324
  3. 3. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610. DOI: 10.1089/thy.2014.033510.1089/thy.2014.0335449062725810047
  4. 4. Eckelt F, Vogel M, Geserick M, Kirsten T, Bae YJ, Baber R, et al. Calcitonin measurement in pediatrics: Reference ranges are gender-dependent, validation in medullary thyroid cancer and effects of thyroid diseases. Clin Chem Lab Med. 2019 Jun;57(8):1242-50. DOI: 10.1515/cclm-2018-118610.1515/cclm-2018-118630794525
  5. 5. Danila R, Livadariu R, Branisteanu D. Calcitonin revisited in 2020. Acta Endocrinol (Buchar) 2019 Oct-Dec;15(4):544-8. DOI: 10.4183/aeb.2019.54410.4183/aeb.2019.544720011532377257
  6. 6. Băetu M, Dobrescu R. Novel markers for early diagnosis and prognostic classification in medullary thyroid carcinoma. Acta Endocrinol (Buchar). 2017 Oct;13(4):519-522. DOI: 10.4183/aeb.2017.51910.4183/aeb.2017.519651654931149228
  7. 7. Hillyard CJ, Oscier DG, Foa R, Catovsky D, Goldman JM. Immunoreactive calcitonin in leukaemia. Br Med J. 1979 Dec;2(6202):1392-3. DOI: 10.1136/bmj.2.6202.139210.1136/bmj.2.6202.13921597057519475
  8. 8. Schwartz KE, Wolfsen AR, Forster B, Odell WD. Calcitonin in nonthyroidal cancer. J Clin Endocrinol Metab. 1979 Sep;49(3):438-44. DOI: 10.1210/jcem-49-3-43810.1210/jcem-49-3-438468977
  9. 9. Toledo SPA, Lourenço DM, Santos MA, Tavares MR, Toledo RA, Correia-DeurI JE de M. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics. 2009 Jul;64(7):699-706. DOI: 10.1590/S1807-5932200900070001510.1590/S1807-59322009000700015271044519606248
  10. 10. Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005 Nov;90(11):6077-6084. DOI: 10.1210/jc.2005-004410.1210/jc.2005-004416091497
  11. 11. Ito Y, Miyauchi A, Kihara M, et al. Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients’ carcinoma death. Endocr J 2016 Jul;63(7):663-7. DOI: 10.1507/endocrj.EJ16-014010.1507/endocrj.EJ16-014027097545
  12. 12. LIAISON® XL | DiaSorin. Available from: https://www.diasorin.com/en/immunodiagnostic-solutions/systems/clia-systems/liaisonr-xl. Accessed Mar 19, 2021.
  13. 13. Elecsys® Calcitonin. Available from: https://diagnostics.roche.com/global/en/products/params/elecsys-calcitonin.html. Accessed Mar 19, 2021.
  14. 14. Kahaly GJ, Algeciras-Schimnich A, Davis TE, Diana T, Feldkamp J, Karger S, et al. United States and european multicenter prospective study for the analytical performance and clinical validation of a novel sensitive fully automated immunoassay for calcitonin. Clin Chem. 2017 Sep;63(9):1489-96. DOI: 10.1373/clinchem.2016.27000910.1373/clinchem.2016.27000928687633
  15. 15. Kratzsch J, Petzold A, Raue F, Reinhardt W, Bröcker-Preuß M, Görges R, et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem. 2011 Mar;57(3):467-74. DOI: 10.1373/clinchem.2010.15168810.1373/clinchem.2010.15168821159900
  16. 16. Shi J, Shi Q, Yuan S, Zhang W. Relationships between serum procalcitonin level, severity and different stresses of non-septic critically ill patients. Rev Romana Med Lab. 2020;28(1):49-56. DOI:10.2478/rrlm-2020-000310.2478/rrlm-2020-0003
  17. 17. Vashist SK, Luong JHT. Handbook of Immunoassay Technologies: Approaches, Performances, and Applications. London: Academic Press; 2018. DOI: 10.1016/B978-0-12-811762-0.05001-510.1016/B978-0-12-811762-0.05001-5
  18. 18. Ross DS. Medullary thyroid cancer: Surgical treatment and prognosis - UpToDate Available from: https://www.uptodate.com/contents/diagnostic-approach-to-and-treatment-of-thyroid-nodules. Accessed Mar 19, 2021.
DOI: https://doi.org/10.2478/rrlm-2021-0024 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Language: English
Page range: 271 - 276
Submitted on: Jun 13, 2021
Accepted on: Jul 13, 2021
Published on: Jul 31, 2021
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2021 Mara Baetu, Alexandru Draghici, Adriana Padure, Stefana Bucur, Andra Caragheorgheopol, Corin Badiu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.